GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Anew Medical Inc.
Shares of Anew Medical, a biopharmaceutical company, are highly speculative. Their price reflects not current revenues, but rather investors' expectations for the success of their developments, their dependence on research news, and their ongoing need for funding.
Share prices of companies in the market segment - Neuro
Anew Medical is a biopharmaceutical company developing treatments for neurodegenerative and other age-related diseases. We've categorized it under the "Neurology" category. The chart below shows how investors value companies working in the anti-aging field.
Broad Market Index - GURU.Markets
Anew Medical is a biopharmaceutical company developing drugs to treat neurodegenerative and other diseases. As a participant in this sector, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it with the company's stock price to assess the industry's prospects.
Change in the price of a company, segment, and market as a whole per day
WENA - Daily change in the company's share price Anew Medical Inc.
Anew Medical, Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the development of its drugs for treating neurodegenerative diseases.
Daily change in the price of a set of shares in a market segment - Neuro
Anew Medical is a biopharmaceutical company focused on developing drugs for the treatment of neurological and oncological diseases. Neurology is a risky area of research. The chart below illustrates the high volatility typical of the biotech sector.
Daily change in the price of a broad market stock, index - GURU.Markets
Anew Medical is a biotech company working on treatments for neurological diseases. Its shares represent a venture-backed bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Anew Medical Inc.
For Anew Medical, Inc., year-over-year performance is a story of developing drugs for rare diseases. Its 12-month market cap depends entirely on progress in preclinical and clinical trials. Success in its neuroscience and oncology approaches could offer new hope for patients.
Annual dynamics of market capitalization of the market segment - Neuro
Anew, a private biotech company, develops drugs targeting the aging process. Its growth depends on success in clinical trials. Its valuation dynamics will reflect investors' faith in its revolutionary, yet highly risky, approach to medicine, potentially outperforming the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Anew Medical, a company developing drugs to treat neurodegenerative diseases, lives by the laws of biotech. Its annual market capitalization dynamics reflect the hopes of scientific breakthroughs. Success or failure in clinical trials completely determines its trajectory, ignoring overall economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Anew Medical Inc.
Anew Medical is a biopharmaceutical company. Its monthly performance is typical for the sector: it depends on progress in its scientific developments and clinical programs. News of its drug trial results are the main drivers of its value.
Monthly dynamics of market capitalization of the market segment - Neuro
Anew Medical is an early-stage biotech company focused on developing treatments for neurodegenerative diseases and other age-related conditions. The chart below illustrates the overall dynamics of the biotech sector, which is the backdrop for the development of such innovative yet risky startups.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Anew Medical is a biopharmaceutical company focused on neuroscience. Its shares are teetering on the edge of anticipation of clinical trial results. Their monthly performance is completely disconnected from the broader market, as the chart clearly illustrates, reflecting a reaction to scientific data rather than general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Anew Medical Inc.
Anew Medical, a company focused on neurodegenerative diseases, whose weekly stock price reflects progress in drug development. News about clinical trials and scientific breakthroughs drives the highly volatile short-term trends typical of the biotech sector.
Weekly dynamics of market capitalization of the market segment - Neuro
Anew Medical shares, like the entire early-stage biotech sector, move in tandem with investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire industry. The chart shows how the company's shares react to this general "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Anew Medical is a development-stage biotech company. Its shares exist in a world of their own, driven by research data. The chart clearly demonstrates that WENA's performance is largely uncorrelated with the market, moving on its own unique news.
Market capitalization of the company, segment and market as a whole
WENA - Market capitalization of the company Anew Medical Inc.
Anew Medical's stock price is a financial bet on the fight against neurodegenerative diseases. Its market cap reflects the company's hopes for its scientific platform to develop new treatments for diseases like amyotrophic lateral sclerosis (ALS). Its performance is a barometer of its research progress and confidence in its approach to this complex problem.
WENA - Share of the company's market capitalization Anew Medical Inc. within the market segment - Neuro
Anew Medical is focused on developing treatments for age-related and neurodegenerative diseases. The company's market cap in the biotech sector reflects investors' assessment of its scientific potential. The small weighting is typical for a research-stage company, but it reflects the company's hopes for a breakthrough in one of the most complex areas of medicine.
Market capitalization of the market segment - Neuro
Anew Medical is a biotech company focused on neurological diseases. The chart below shows the overall market capitalization of this complex sector. Its dynamics are a barometer of investor hopes that science will find the keys to curing brain diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Anew Medical is a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. Its market cap is a financial bet on a scientific breakthrough. Its value reflects investors' hopes for the success of their drugs in one of the most challenging areas of medicine.
Book value capitalization of the company, segment and market as a whole
WENA - Book value capitalization of the company Anew Medical Inc.
Anew Medical is an early-stage biopharmaceutical company. Its book value is primarily comprised of cash from investors. The chart below shows how this capital is spent on preclinical research. This represents its financial "headroom" for developing new drugs.
WENA - Share of the company's book capitalization Anew Medical Inc. within the market segment - Neuro
Anew Medical is a biotech company focused on treating neurodegenerative diseases. Its core capital is intellectual property. The share of physical assets will reflect its research-focused model, where its primary tangible assets are its high-tech laboratories.
Market segment balance sheet capitalization - Neuro
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Anew Medical, which develops drugs to treat neurodegenerative diseases, looks like a "lightweight." Its value lies in its scientific platform and patents, not in its large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Anew Medical is a biotech company focused on developing drugs for rare diseases. Its assets are not plants, but intellectual property and research data. The company's balance sheet is the value of scientific research into solutions for diseases that affect a small number of people but have enormous real-world consequences.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Anew Medical Inc.
Anew Medical's balance sheet is its patents and research. Its market capitalization is a speculative bet on the success of its drugs. The MvsBCap_Co chart shows how many times the "hope" for a new drug is worth compared to the company's modest tangible assets.
Market to book capitalization ratio in a market segment - Neuro
Anew Medical is a biotech company developing drugs for the treatment of age-related and neurodegenerative diseases. Its value lies in its scientific developments. The chart shows a speculative estimate of its potential, which depends entirely on the success of clinical trials.
Market to book capitalization ratio for the market as a whole
Anew Medical is developing treatments for neurodegenerative diseases. As with most biotech companies, investors evaluate future prospects rather than current assets. The difference between the market value and book value in this chart is essentially a premium for the market's belief in the potential success of the company's research.
Debts of the company, segment and market as a whole
WENA - Company debts Anew Medical Inc.
Anew Medical, Inc., a preclinical biopharmaceutical company, uses seed capital to fund its research. This graph likely shows minimal or no traditional debt, as companies at this stage typically rely on equity financing. Debt may be acquired later to finance clinical trials.
Market segment debts - Neuro
Anew Medical is a biopharmaceutical company likely focused on aging-related diseases or neuroscience. Being in the early stages of research, the company is entirely dependent on external funding. This chart may illustrate the financial health of a startup seeking capital to advance its scientific ideas.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Anew Medical Inc.
Anew Medical is an early-stage biotech company focused on neuroscience. Its financial health depends entirely on its ability to attract capital for research. This chart shows its level of financial risk. For such a company, any debt is a significant bet on the future success of its research, as it has no revenue of its own.
Market segment debt to market segment book capitalization - Neuro
Anew Medical is a clinical-stage biopharmaceutical company, likely focused on neuroscience or age-related diseases. Financing clinical trials requires capital. The chart shows how the company's debt load for R&D funding compares to the market capitalization and risks of the overall biotech sector.
Debt to book value of all companies in the market
Anew Medical (WENA) is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases and oncology. Being in the research stage, the company has no revenue. This chart shows the overall market leverage. It serves as a contrast, emphasizing that WENA's future depends on the success of investor-funded R&D, not debt.
P/E of the company, segment and market as a whole
P/E - Anew Medical Inc.
This indicator is likely absent for Anew Medical, Inc., a company in early development. The valuation will be based on investors' faith in the company's scientific platform for treating neurodegenerative and other diseases. The chart's dynamics will depend entirely on news about preclinical and clinical trials.
P/E of the market segment - Neuro
This is the average P/E for biotech companies. For Anew Medical, which is in early development, it serves as a benchmark. It reflects the overall level of investor confidence in the sector, providing context for Anew's valuation, which is a bet on its unique scientific approach to treating complex diseases.
P/E of the market as a whole
Anew Medical is a biotech company focused on developing treatments for neurodegenerative diseases and cancer. Its valuation, like many early-stage companies, is based on the potential of its scientific platform. This chart shows the overall risk appetite of investors, helping to understand how the overall investment climate in biotech impacts Anew Medical's ability to fund its research.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Anew Medical Inc.
Anew Medical is an early-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. This chart, if it exists, reflects purely speculative expectations. It represents analysts' assessment of the company's scientific potential and its chances of long-term success, not near-term profitability.
%20P%2FE%20Anew%20Medical%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Anew-Medical-Inc.&v=1772619825822 "Chart of the company's future (projected) P/E Anew Medical Inc.")
Future (projected) P/E of the market segment - Neuro
Anew Medical, Inc. is a biotech company specializing in developing treatments for neurodegenerative diseases and oncology. This chart shows average expectations for the biotech sector. WENA's position may indicate the extent to which investors believe in its scientific platform and the potential of its developments to create breakthrough treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772619825838 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Anew Medical, Inc. is a biotech company focused on developing drugs for neurodegenerative diseases. Its value is based on its scientific potential. Overall investor sentiment, as reflected in this chart, influences the availability of capital for long-term and expensive research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772619825856 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Anew Medical Inc.
Anew Medical, Inc. is a biopharmaceutical company developing treatments for both rare and common diseases using gene therapy approaches. This chart reflects cutting-edge medical research. It shows investments in scientific development, with future profits dependent on the success of their therapeutic platforms in clinical trials.
Profit of companies in the market segment - Neuro
Anew Medical, Inc. is a biotech company focused on developing therapies for neurodegenerative diseases and oncology. Profitability in the neuroscience sector, as this chart shows, comes from finding breakthroughs in treating complex diseases like Alzheimer's. For WENA, success depends on clinical trial results and the validation of their scientific approach.
Overall market profit
Anew Medical, Inc., a biopharmaceutical company focused on neurodegenerative diseases, operates in a field driven by science. The need for treatments for conditions like Alzheimer's is enormous and unaffected by the economic situation, as this chart illustrates. The company's success is determined solely by the results of its clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Anew Medical Inc.
Anew Medical develops therapeutics for the treatment of neurodegenerative diseases. This chart shows analyst forecasts, which are essentially an assessment of the scientific potential of its developments. The forecast dynamics reflect the market's confidence in the success of its clinical programs.
%20profit%20of%20the%20company%20Anew%20Medical%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Anew-Medical-Inc.&v=1772619825948 "Graph of future (projected) profit of the company Anew Medical Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Anew Medical, Inc. is a biotechnology company focused on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart shows the revenue forecast for the neuroscience sector, reflecting investor and public expectations for the emergence of effective therapies to combat previously incurable diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772619826000 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Anew Medical is an early-stage biopharmaceutical company. Its value is based on the future potential of its research and development, not on current revenue. The overall economic outlook, shown in the chart, influences its value through the availability of risk capital, which becomes scarce during periods of market pessimism.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772619826039 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Anew Medical Inc.
Anew Medical is a biotech company working on treating neurodegenerative diseases. Being in the early clinical stage, it does not generate revenue. The chart represents a speculative investor valuation based solely on faith in its scientific approach and potential future breakthroughs, not on any current commercial success.
P/S market segment - Neuro
Anew Medical, Inc. is a biotech company specializing in developing treatments for neurodegenerative diseases and oncology. The chart shows the average revenue valuation in the biotech industry. It helps understand how highly investors value its scientific developments and potential for breakthrough drugs compared to the industry.
P/S of the market as a whole
Anew Medical, Inc. is a biotech company focused on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Its valuation is based on its scientific potential. A graph of average market revenue estimates shows that it is an investment in the hope of a breakthrough in the treatment of serious diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Anew Medical Inc.
Anew Medical is a clinical-stage biotech company specializing in neurodegenerative diseases. The chart is a measure of investor optimism. It values the company based on the significant future revenue its therapy could generate if clinical trials are successful and the company reaches market.
%20P%2FS%20Anew%20Medical%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Anew-Medical-Inc.&v=1772619826233 "The graph of the company's future (projected) P/S Anew Medical Inc.")
Future (projected) P/S of the market segment - Neuro
Anew Medical, Inc. is a biotechnology company focused on developing drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart shows the average future sales estimates for neuroscience companies. It provides context for understanding how the market views Anew's scientific approach and its chances of success.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772619826312 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Anew Medical, Inc. is a biotech company working on the treatment of neurodegenerative diseases. Its value is driven by scientific breakthroughs. This revenue guidance chart is of little significance to the company. Investors are focused on the potential of its platform to address complex medical problems for which effective drugs are currently unavailable.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772619826378 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Anew Medical Inc.
Anew Medical is a biotech company developing treatments for neurodegenerative diseases and cancer. Being in the research and development phase, it typically does not generate sales revenue. This graph could eventually reflect its commercial success if its drugs pass clinical trials and receive approval.
Sales of companies in the market segment - Neuro
Anew Medical, Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The company is seeking new approaches to combating these devastating illnesses. This chart shows total revenue in the neuroscience sector, reflecting the level of investment and scientific progress in this complex field of medicine.
Overall market sales
Anew Medical is a biopharmaceutical company focused on treating neurodegenerative diseases. Its prospects depend on the success of clinical trials and partnerships. The overall economic situation, shown in this chart, impacts the availability of capital for funding long-term biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Anew Medical Inc.
Anew Medical develops drugs to treat rare diseases and conditions associated with aging. Its future depends entirely on the success of its therapeutic candidates in clinical trials and regulatory approval. This timeline reflects analyst expectations for the commercial potential of its research developments.
%20sales%20of%20the%20company%20Anew%20Medical%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Anew-Medical-Inc.&v=1772619826599 "Schedule of future (projected) sales of the company Anew Medical Inc.")
Future (projected) sales of companies in the market segment - Neuro
Anew Medical, Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The chart shows forecasts for the neuroscience pharmaceutical sector. The company's success depends entirely on the results of its clinical trials in this complex area.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772619826622 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Anew Medical is in the early stages of developing treatments for neurodegenerative diseases and cancer. The company's future depends entirely on the success of its scientific research and its ability to raise capital. This timeline, reflecting investor sentiment, impacts the availability of funding for speculative biotech companies with very long time horizons to commercialization.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772619826623 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Anew Medical Inc.
Anew Medical, Inc. is a biopharmaceutical company focused on developing drugs for rare diseases and neurodegenerative disorders. While in the development stage, it incurs significant research expenses. This chart illustrates the company's investments in research in hopes of creating breakthrough drugs.
Market segment marginality - Neuro
Anew Medical is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative diseases and cancer. This chart shows the average revenue in the pharmaceutical industry. As an early-stage company, its future ability to exceed this figure will depend entirely on the success of its scientific developments in clinical trials.
Market marginality as a whole
Anew Medical, Inc. is a biotechnology company focused on developing drugs for the treatment of neurodegenerative diseases and oncology. It is in the early stages of development, and its financial activities are driven by investments in science. This graph of total profitability clearly demonstrates the gap between the cost of research and the current profitability of established corporations.
Employees in the company, segment and market as a whole
Number of employees in the company Anew Medical Inc.
Anew Medical is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases and cancer. While in the research stage, the company relies on its scientific team. This graph shows the small and highly specialized staff that forms the core of its efforts to advance new therapies.
Share of the company's employees Anew Medical Inc. within the market segment - Neuro
Anew Medical is a biotech company focused on developing therapeutics for both rare and common diseases, including neurodegenerative diseases. The R&D team is small but highly specialized. This graph reflects its status as an R&D-focused company, where value is created by the quality of scientific expertise, not the number of employees.
Number of employees in the market segment - Neuro
Anew Medical, Inc. is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative diseases and oncology. The growth of its small and focused scientific team, which can be seen in the graph, is an indicator of progress in preclinical and early clinical trials.
Number of employees in the market as a whole
Anew Medical is an early-stage biotech company focused on developing treatments for neurodegenerative and rare diseases. This chart shows a typical team structure for an R&D startup. The minimal team consists of key scientific staff. Any change in its size is a significant event, reflecting progress.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Anew Medical Inc. (WENA)
Anew Medical is a biotech company developing treatments for neurodegenerative diseases. Like most companies in this sector, its market capitalization is not based on current sales, but rather on market expectations for its scientific developments. This metric reflects the value of its intellectual property (patents) per scientist working in its lab.
%20of%20the%20company%20Anew%20Medical%20Inc.%20(WENA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Anew-Medical-Inc.-WENA&v=1772619826820 "Chart of market capitalization per employee (in thousands of dollars) of the company Anew Medical Inc. (WENA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Anew Medical, Inc. is a biotechnology company focused on developing treatments for neurodegenerative diseases and oncology. Its market capitalization is based on its research potential. This chart shows the company's high market valuation of intellectual capital per research scientist.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772619826847 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Anew Medical develops treatments for age-related diseases, including gene therapy. This chart illustrates the valuation of this longevity biotech startup. The very high per-employee valuation reflects the investors' belief that the small scientific team is on the verge of discoveries that could extend healthy life.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772619826892 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Anew Medical Inc. (WENA)
Anew Medical is an early-stage biotech company focused on rare diseases and neurodegeneration (Alzheimer's). The company is not profitable. This chart shows the net loss (R&D costs) per scientist working on future drugs in this complex field.
%20Chart%20Anew%20Medical%20Inc.%20(WENA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Anew-Medical-Inc.-WENA&v=1772619826916 "Company Profit Per Employee (in thousands of dollars) Chart Anew Medical Inc. (WENA)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Anew Medical is a biotech company developing drugs to treat neurodegenerative diseases and oncology. Being in the early stages of R&D, the company is not profitable. This chart shows the cash burn per employee. It serves as a benchmark for assessing how intensively Anew invests in its research programs compared to other biotech startups.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772619826956 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Anew Medical is a clinical-stage biotech company focused on developing treatments for neurodegenerative diseases and oncology. The company has no approved products and is not profitable. This chart shows a negative value—the investment (loss) per scientist working on new therapies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772619826999 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Anew Medical Inc. (WENA)
Anew Medical, Inc. is an early-stage biotech company focused on neuroscience. For a company without commercial products, this timeline is likely zero. It will only begin to grow after concluding a licensing agreement or partnership that will generate initial revenue from monetizing its research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Anew-Medical-Inc.-WENA&v=1772619827038 "Sales chart per company employee Anew Medical Inc. (WENA)")
Sales per employee in the market segment - Neuro
Anew Medical (WENA) is an early-stage biotech focused on neurodegenerative diseases (Alzheimer's) and rare cancers. The company has no approved products and, therefore, no commercial revenue. This graph doesn't reflect their value. Staff productivity here would be zero, as the entire staff is focused on R&D.
Sales per employee for the market as a whole
Anew Medical is a biotech company focused on neurological and degenerative diseases. At the R&D stage, this metric reflects investment in the future. A team of scientists is working on developing a platform, and this metric will only increase if clinical trials are successful and their research is commercialized.
Short shares by company, segment and market as a whole
Shares shorted by company Anew Medical Inc. (WENA)
Anew Medical (WENA) is a biotech company focused on developing drugs for rare diseases, including neurodegenerative diseases and oncology. This metric reflects bearish bets. Market skepticism is high: investors doubt the success of their early clinical programs or their ability to fund expensive development.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Anew-Medical-Inc.-WENA&v=1772619827123 "Short Shares Chart for the Company Anew Medical Inc. (WENA)")
Shares shorted by market segment - Neuro
Anew Medical (WENA) is an early-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases such as Alzheimer's. This chart illustrates the overall bearish sentiment across the entire neuroscience biotech sector. This field is known for its high risks, so the surge in short positions in the sector reflects deep investor skepticism about new developments in this field.
Shares shorted by the overall market
Anew Medical is an early-stage biotech company. This chart illustrates the overall market pessimism. As fear mounts, investors sell off biotech microcaps en masse. They see WENA as a money-burning venture on high-risk R&D and prefer to exit the stock without waiting for news on trials in a volatile market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Anew Medical Inc. (WENA)
Anew Medical (WENA) is a biotech company developing drugs to treat neurodegenerative diseases like ALS. This is a high-risk area. This chart measures the strength of speculative moves. It shows when the stock is "overheated" (above 70) due to early data or "oversold" (below 30) due to a lack of news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Anew-Medical-Inc.-WENA&v=1772619827164 "RSI 14 indicator chart for the company's stock Anew Medical Inc. (WENA)")
RSI 14 Market Segment - Neuro
Anew Medical is a biotech company, an Alzheimer's hunter. The Neuro (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is WENA's growth due to their R&D or is the entire biotech sector simply overheated by expectations?
RSI 14 for the overall market
Anew Medical (WENA) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast WENA (Anew Medical Inc.)
Anew Medical is a clinical-stage biotech company focused on developing drugs for the treatment of neurodegenerative diseases (Alzheimer's, ALS). This chart shows the average target price. Analysts' forecasts are based on an assessment of preclinical and early clinical data, as well as the potential of its R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-WENA-Anew-Medical-Inc.&v=1772619827236 "A chart showing analyst consensus forecasts for the expected stock price. WENA (Anew Medical Inc.)")
The difference between the consensus estimate and the actual stock price WENA (Anew Medical Inc.)
Anew Medical is an early-stage biotech company developing drugs to treat neurodegenerative diseases (Alzheimer's, Parkinson's). This chart measures the gap between the current share price and the consensus target price. It shows the "venture" potential (and high risks) analysts attribute to their R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-WENA-Anew-Medical-Inc.&v=1772619827241 "A chart showing the difference between the consensus forecast and the actual stock price. WENA (Anew Medical Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Anew Medical (WENA) is an early-stage biotech company developing drugs to treat neurodegenerative diseases (Alzheimer's, ALS). This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe in R&D breakthroughs in treating brain diseases or consider the sector an R&D "graveyard."
Analysts' consensus forecast for the overall market share price
Anew Medical (WENA) is a micro-cap clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Anew Medical Inc.
Anew Medical is a biotech R&D company focused on neuroscience. It's a binary risk business: all or nothing. This chart is a pure indicator of faith in their R&D. It doesn't reflect current sales (they don't have any), but rather a speculative assessment of their scientific progress, clinical trial data, and their chances of regulatory approval.
AKIMA Market Segment Index - Neuro
Anew Medical (WENA) is a neurobiotech company targeting Alzheimer's. Their approach isn't to treat plaques, but to restore brain function. In this highly complex area of R&D, understanding relative strength is crucial. This chart compares their composite index to the sector average, showing their position.
The AKIM Index for the overall market
Anew Medical is a company developing therapies for neurodegenerative diseases and cancer, as well as gene therapy (Klotho). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative early-stage scientific story compares to overall economic trends.
